Roche touts 2-year efficacy data for SMA therapy Evrysdi; NIH funds new network to study flu and viruses with ‘pandemic potential’
Two years after therapy, 61% of babies with spinal muscular atrophy Type 1 treated with Roche’s Evrysdi (risdiplam) were able to sit up without support for at least five seconds compared with just 29% of patients after a year, the drugmaker said Thursday.
As part of the FIREFISH-2 Phase III study, researchers tested Evrysdi’s ability to help 41 infant patients sit up without support at 5 and 30 seconds. Data showed that 44% of patients were able to sit without support for 30 seconds at the two-year check-in compared with 17% after one year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
